Recent clinical trials have confirmed the discovery of a new medicament for bone healing. After Sumamed, this is a new medication that is completely invented by Croatian scientists and which has already been tested on 10 patients in the Zagreb Trauma Clinic and the two patients in Vienna. The drug Osteogrow will be on the market for three years and by the end of this year will treat 75 patients. The drug is intended for patients with the problem of bone healing, as well as those who need to supplant part of the bone missing. It works so that the 1 oz of their own blood clot patient device, and then in the blood is added bone morphogenetic protein and all put in place where is necessary to “create” new bone. Osteogrow is injected at the place of fracture or for buildibg bone grafts. For this drug was granted patent in the United States, Europe, Canada, Australia. Manager and Project Coordinator Slobodan Vukičević can not hide the excitement and success buy the fact that for the first time in the history of medicine Croatian academic community without the help of the pharmaceutical industry developed and tested a biological drug. This is the first time that the European Commission has entrusted the coordination of the project to a Croatian institution, the Medical Faculty in Zagreb, with the help of European partners from England, Germany, Sweden, Czech Republic, Austria and Bosnia and Herzegovina. The project was funded in the amount of EUR 5.8 million, which created the cheapest cure for global application. The team of experts to design and create drug worked intensively in the last four years and involved 40 people, respectively top and scientific clinicians unknown to the public. To date, treatment of patients medicated with Osteogrow did not report side effects no negative indications. Its major role is expected in the treatment of back pain caused by degenerative changes of the spine. This is the first time that the results of the study drug shown to the world’s leading scientists in the field of medicine bone disease at Oxford. The discovery and preclinical development of drug was presented by Lovorka Grgurević from Medical faculty Zagreb, while the project manager presented the future of medicine in the treatment of patients with degenerative changes of the spine. Most responsible for the development and use of the drug, in addition to the before mentioned Slobodan Vukičević and Lovorka Grgurević, there is Hermann Oppermann from Genera Research, Mihaela Perić who conducted toxicological tests, Ruth Paul from the UK who led the program in accordance with regulations and laws. Experts in drug development are also Dragan Đurđević and Tomislav Vlahović from the Sisters of Mercy Zagreb who designed the protocol for the clinical study of the drug in patients with distal radius fractures, Ismet Gavrankapetanović and Mehmed Jamakosmanović from the Department of Orthopaedic Sarajevo, Reinhard Windhager and Catharina Chiari from General University Hospital in Vienna, and Snježana Martinović from Smart Medic.